About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veru Inc (NQ: VERU )

0.9406 -0.0094 (-0.99%)
Streaming Delayed Price Updated: 11:02 AM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veru Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Bragar Eagel & Squire, P.C. Is Investigating Accelerate Diagnostics, and Veru and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Veru Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Why Veru Stock Was Losing One-Third of Its Value This Week
The future of a top pipeline drug now looks much dimmer. 
Via The Motley Fool
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Veru Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why Veru Stock Is Cratering Today
A negative vote on one of its drugs is weighing on the biotech's stock price. 
Via The Motley Fool
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Is VERU Stock Down 50% Today?
The regulatory hammer is hitting VERU stock investors hard today as the FDA denies a crucial authorization for Veru's Covid-19 drug. 
Via InvestorPlace
Dow Jumps Over 1,000 Points; Digital Turbine Shares Spike Higher
U.S. stocks traded sharply higher toward the end of trading, with the NASDAQ Composite jumping over 6% on Thursday. 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Veru Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Oracle Layoffs 2022: What to Know About ORCL Job Cuts, Hiring Freeze
Oracle (ORCL) layoffs are worth checking out on Thursday as investors keep track of tech companies that are cutting employees. 
Via InvestorPlace
Dow Soars Over 900 Points; Nasdaq Over 600
Inflation data for October is sending stocks to the moon today. 
Via Talk Markets
Why Veru Stock Is Skyrocketing Today
Investors are reacting positively to an FDA briefing document. 
Via The Motley Fool
Why Magnite Shares Are Trading Higher By Over 45%? Here Are 69 Stocks Moving In Thursday's Mid-Day Session
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares climbed 172% to $0.2769 after dipping 40% on Wednesday. Fast Radius received Bankruptcy court approval of first day motions related to the company's... 
Via Benzinga
Nasdaq Surges 600 Points; Gold Gains 2%
U.S. stocks traded sharply higher midway through trading , with the Nasdaq Composite gaining 600 points on Thursday. 
Via Benzinga
Cano Health, Vacasa, Organogenesis, And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Nasdaq surging more than 500 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Dow Jumps Over 700 Points; US Inflation Rate Falls In October
U.S. stocks traded sharply higher this morning , following the release of inflation data on Thursday. 
Via Benzinga
Veru Stock Plummets 65% After FDA Advisors Vote Down Cancer-Turned-Covid Drug
The FDA isn't bound by the advisors' recommendation. But it does consider their vote. 
Via Investor's Business Daily
How Is The Market Feeling About Veru?
Veru's (NASDAQ:VERU) short percent of float has fallen 12.12% since its last report. The company recently reported that it has 14.69 million shares sold short, which is 22.76% of all regular shares... 
Via Benzinga
Veru Stock Could Retrace Week's 45% Gain As FDA Panel Votes Against COVID-19 Drug
Veru Inc. 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
VERU Stock Soars 40% Despite Uncertainty Surrounding Covid-19 Drug
While the FDA may have some questions regarding Veru’s Covid-19 therapeutic, investors remain optimistic about VERU stock. 
Via InvestorPlace
Dow Surges 400 Points; Crude Oil Down 1%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 400 points on Monday. 
Via Benzinga
Medical Leader Veru Catapults As FDA Preps To Discuss Cancer Drug For Covid
The company's drug could be used in a specific population of Covid patients. 
Via Investor's Business Daily
Veru Shares Jump Over 40% Despite FDA Staff Raises Uncertainties Over Its COVID-19 Therapy
Veru Inc (NASDAQ: VERU) is set to face an FDA Advisory Committee meeting on Wednesday regarding its emergency use authorization (EUA) application for the oral COVID-19 therapy sabizabulin. 
Via Benzinga
$100 Invested In Veru 5 Years Ago Would Be Worth This Much Today
Veru (NASDAQ:VERU) has outperformed the market over the past 5 years by 56.49% on an annualized basis producing an average annual return of 64.35%. Currently, Veru has a market capitalization of $1.22... 
Via Benzinga
Dow Jumps Over 200 Points; Verve Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Monday. 
Via Benzinga
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
US Stocks Mixed; Dow Rises Over 50 Points
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 50 points on Monday. 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.